William Blair analyst Matthew Phipps downgraded Kezar Life Sciences (KZR) to Market Perform from Outperform without a price target The company announced it has been unable to align with the FDA on a registrational trial for zetomipzomib in autoimmune hepatitis and is initiating a process to explore strategic alternatives, the analyst tells investors in a research note. The firm is surprised to see the FDA refusing to host a Type C meeting. Considering Kezar’s current cash balance and liabilities, Blair believes a potential acquisition in the $6 to $7 per share range could be feasible.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZR:
- Kezar Life Sciences Faces Uncertainty with Hold Rating Amid FDA Setback and Strategic Alternatives Exploration
- Kezar Life Sciences downgraded to Hold from Buy at Jefferies
- Closing Bell Movers: CSX gains over 2% on earnings beat; OZK slips on miss
- Kezar Life Sciences Faces FDA Challenges in Drug Program
- Kezar Life Sciences trading resumes